Transgene SA (TNG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Transgene SA (TNG) has a cash flow conversion efficiency ratio of -0.152x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-18.55 Million ≈ $-21.69 Million USD) by net assets (€121.73 Million ≈ $142.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TNG company net worth for the company's overall valuation and market capitalisation.
Transgene SA - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Transgene SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Transgene SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Transgene SA ranked by their cash flow conversion efficiency. Explore earnings quality score of Transgene SA to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Live Oak Acquisition Corp. V Class A Ordinary Shares
NASDAQ:LOKV
|
-0.003x |
|
Shenzhen Keybridge Communications Co Ltd
SHE:002316
|
0.035x |
|
Halla Holdings Corp
KO:060980
|
0.018x |
|
Akebia Ther
NASDAQ:AKBA
|
0.955x |
|
Sichuan Langsha Holding Ltd
SHG:600137
|
-0.016x |
|
Papercorea
KO:001020
|
-0.054x |
|
Asia Cement
KO:002030
|
0.032x |
|
Bioteque
TWO:4107
|
0.036x |
Annual Cash Flow Conversion Efficiency for Transgene SA (1997–2025)
The table below shows the annual cash flow conversion efficiency of Transgene SA from 1997 to 2025. View TNG live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €121.73 Million ≈ $142.32 Million |
€-36.74 Million ≈ $-42.95 Million |
-0.302x | +80.52% |
| 2024-12-31 | €15.20 Million ≈ $17.78 Million |
€-23.55 Million ≈ $-27.53 Million |
-1.549x | +30.26% |
| 2023-12-31 | €15.61 Million ≈ $18.25 Million |
€-34.67 Million ≈ $-40.53 Million |
-2.221x | -313.91% |
| 2022-12-31 | €37.84 Million ≈ $44.24 Million |
€-20.30 Million ≈ $-23.74 Million |
-0.537x | -12.89% |
| 2021-12-31 | €67.21 Million ≈ $78.57 Million |
€-31.94 Million ≈ $-37.34 Million |
-0.475x | +16.91% |
| 2020-12-31 | €50.25 Million ≈ $58.75 Million |
€-28.74 Million ≈ $-33.60 Million |
-0.572x | -67.66% |
| 2019-12-31 | €65.70 Million ≈ $76.81 Million |
€-22.41 Million ≈ $-26.20 Million |
-0.341x | +55.88% |
| 2018-12-31 | €36.70 Million ≈ $42.91 Million |
€-28.38 Million ≈ $-33.18 Million |
-0.773x | +38.59% |
| 2017-12-31 | €28.09 Million ≈ $32.84 Million |
€-35.37 Million ≈ $-41.35 Million |
-1.259x | -74.35% |
| 2016-12-31 | €46.50 Million ≈ $54.37 Million |
€-33.59 Million ≈ $-39.26 Million |
-0.722x | +57.54% |
| 2015-12-31 | €26.55 Million ≈ $31.04 Million |
€-45.15 Million ≈ $-52.79 Million |
-1.701x | -125.29% |
| 2014-12-31 | €71.84 Million ≈ $83.99 Million |
€-54.24 Million ≈ $-63.41 Million |
-0.755x | +14.82% |
| 2013-12-31 | €56.62 Million ≈ $66.20 Million |
€-50.19 Million ≈ $-58.67 Million |
-0.886x | -72.06% |
| 2012-12-31 | €99.58 Million ≈ $116.42 Million |
€-51.29 Million ≈ $-59.97 Million |
-0.515x | -64.95% |
| 2011-12-31 | €141.42 Million ≈ $165.33 Million |
€-44.16 Million ≈ $-51.63 Million |
-0.312x | -130.02% |
| 2010-12-31 | €183.62 Million ≈ $214.67 Million |
€-24.93 Million ≈ $-29.14 Million |
-0.136x | +50.28% |
| 2009-12-31 | €68.56 Million ≈ $80.16 Million |
€-18.72 Million ≈ $-21.89 Million |
-0.273x | -10.00% |
| 2008-12-31 | €94.22 Million ≈ $110.16 Million |
€-23.39 Million ≈ $-27.34 Million |
-0.248x | -1228.28% |
| 2007-12-31 | €110.94 Million ≈ $129.70 Million |
€-2.07 Million ≈ $-2.42 Million |
-0.019x | +98.18% |
| 2006-12-31 | €18.98 Million ≈ $22.19 Million |
€-19.54 Million ≈ $-22.84 Million |
-1.029x | +23.32% |
| 2004-12-31 | €14.23 Million ≈ $16.64 Million |
€-19.11 Million ≈ $-22.34 Million |
-1.343x | -154.45% |
| 2003-12-31 | €34.52 Million ≈ $40.36 Million |
€-18.21 Million ≈ $-21.29 Million |
-0.528x | -81.78% |
| 2002-12-31 | €55.21 Million ≈ $64.54 Million |
€-16.02 Million ≈ $-18.73 Million |
-0.290x | -35.93% |
| 2001-12-31 | €73.63 Million ≈ $86.08 Million |
€-15.72 Million ≈ $-18.38 Million |
-0.214x | +66.64% |
| 2000-12-31 | €34.79 Million ≈ $40.67 Million |
€-22.27 Million ≈ $-26.03 Million |
-0.640x | -155.78% |
| 1999-12-31 | €55.48 Million ≈ $64.86 Million |
€-13.88 Million ≈ $-16.23 Million |
-0.250x | +45.04% |
| 1998-12-31 | €73.49 Million ≈ $85.92 Million |
€-33.47 Million ≈ $-39.13 Million |
-0.455x | +19.95% |
| 1997-12-31 | €20.68 Million ≈ $24.18 Million |
€-11.77 Million ≈ $-13.76 Million |
-0.569x | -- |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) posi… Read more